(1)

Novel trifluoromethylated enobosarm analogues show very potent antiandrogen activity in prostate cancer cells, and cells with acquired bicalutamide resistance whilst maintaining tissue selectivity in vivo

ea0042oc4 | (1)

The use of apolipoprotein D as a biomarker for androgen sensitivity identifies a new type of androgen insensitivity syndrome that is not associated with a mutation in the androgen receptor gene

ea0042oc5 | (1)

What is the impact of AR modulation in the decidualisation of hESCs from women with endometriosis?

ea0042oc6 | (1)

Transgender: biological model for steroid action

ea0042oc7 | (1)

Identification of AR genomic targets in mesenchymal cell subsets during prostate development

ea0042oc8 | (1)

Fibroblast AR signalling in prostate cancer: Unique regulation of AR signalling, and associations with patient outcomes by influencing cancer progression and invasion

ea0042oc9 | (1)

Chromatin relaxation is a feature of advanced prostate cancer

ea0042oc10 | (1)

Glycosylation is a global target for androgen control in prostate cancer cells

ea0042oc11 | (1)

Sex steroid deficiency alters renal calcium transporter expression independently of its effect on bone resorption

ea0042oc12 | (1)

Rapid cycling high dose testosterone (Bipolar Androgen Therapy) as therapy for men with metastatic castrate-resistant prostate cancer (mCRPC)

ea0042oc13 | (1)

The role of nuclear steroid receptors in castration-resistant prostate cancer (CRPC)

ea0042oc14 | (1)

Optimization of an engineered microrepressor for the treatment of castration-resistant prostate cancer

ea0042oc15 | (1)

In vivo imaging reveals prostate pathology in the PTEN knockout murine model of prostate cancer

ea0042oc16 | (1)

Genomic analysis of Enzalutamide-resistant cells

ea0042oc17 | (1)

Endocrine Abstracts

Androgens 2016

Oral Communications

Non-classical testosterone signaling in the testis

Control of androgen bioactivity by sex hormone-binding globulin

Novel trifluoromethylated enobosarm analogues show very potent antiandrogen activity in prostate cancer cells, and cells with acquired bicalutamide resistance whilst maintaining tissue selectivity in vivo

The use of apolipoprotein D as a biomarker for androgen sensitivity identifies a new type of androgen insensitivity syndrome that is not associated with a mutation in the androgen receptor gene

What is the impact of AR modulation in the decidualisation of hESCs from women with endometriosis?

Transgender: biological model for steroid action

Identification of AR genomic targets in mesenchymal cell subsets during prostate development

Fibroblast AR signalling in prostate cancer: Unique regulation of AR signalling, and associations with patient outcomes by influencing cancer progression and invasion

Chromatin relaxation is a feature of advanced prostate cancer

Glycosylation is a global target for androgen control in prostate cancer cells

Sex steroid deficiency alters renal calcium transporter expression independently of its effect on bone resorption

Rapid cycling high dose testosterone (Bipolar Androgen Therapy) as therapy for men with metastatic castrate-resistant prostate cancer (mCRPC)

The role of nuclear steroid receptors in castration-resistant prostate cancer (CRPC)

Optimization of an engineered microrepressor for the treatment of castration-resistant prostate cancer

In vivo imaging reveals prostate pathology in the PTEN knockout murine model of prostate cancer

Genomic analysis of Enzalutamide-resistant cells

miR-32 promotes replicative changes in prostate epithelium in vivo

BiosciAbstracts